
Galenica announces $1.53 billion Replysa acquisition
pharmafile | July 21, 2016 | News story | Research and Development, Sales and Marketing | Relypsa, Vifor pharma, galenica
Galenica has announced that it has entered into an agreement to acquire Relypsa in a deal worth $1.53 billion, which will strengthen its Vifor Pharma business unit before it launches as its own independent speciality pharma company.
The group, which boasts a market cap of $8.37 billion, intends to split into two independent listed companies, with this latest deal granting Vifor Pharma a dedicated US commercial organisation and global rights to Veltassa, a potassium binder for the treatment of hyperkalaemia. Their $1.53 billion bid for Relypsa translates to a cost of $32 per share.
The takeover of Relypsa will allow Vifor access to a pipeline of polymeric medicines for patients with conditions that can be addressed in the gastrointestinal tract. Veltassa, in particular, has been pinpointed by the group as a potential blockbuster medicine.
Etienne Jomod, executive chairman of Galenica, says: “The combination of Vifor Pharma and Relypsa is an important step towards achieving our goal of building a world-leading speciality pharmaceutical company focused on nephrology, cardiology and gastroenterology medicines. This acquisition will give Vifor Pharma direct access to the key US market, enabling us to maximise the potential of our compelling product portfolio and enhancing our growing attraction as an international partner of choice.”
Sean Murray
Related Content

NICE reverses previous decision to recommend Vifor Pharma’s Veltassa for NHS treatment of hyperkalaemia
It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for …

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of …

Working Life, Vifor Pharma, Derek Williams
How did you find your way into your current role? I began my career in …






